Presentations
Rethinking the Epidemiology of Tuberculosis
Infection
The First Global Symposium on
Interferon-γ Assays
The First Global Symposium on Interferon-Gamma Assays was held on 21-22 February 2007 in Vancouver BC, Canada.
This symposium, chaired by Tony Catanzaro, MD, of San Diego and Lee Reichman of Newark NJ, brought together almost
200 scientists, to hear and discuss eight state-of-the-art presentations from invited experts in plenary sessions
and 63 submitted poster presentations as judged by an independent academic committee.
Topics ranged from the science underpinning Interferon gamma assays to performance in various clinical settings
and cost effectiveness relative to traditional tuberculin testing.
With the cooperation of the STOP TB Partnership and Cellestis, FIND is proud to present the PowerPoint slide presentations of each of the speakers.
It is hoped that this symposium and the promulgation of the data in this forum will promote scientific
interaction as well as further research and discussion that will lead to the swift but rational adoption of these assays to clinical practice.
Challenging the ‘Dogma’
Session 1: Latency and the Risk of Active TB (Basic Science): What Do We Currently Know?
[n/a]. Peter Andersen DVM, DMSc. (Statens Serum Institut, Denmark):
Specific Antigens and Assays for Latent TB
1a. David Lewinsohn MD, PhD. (Oregon Health & Science University, USA):
The Human Response to Latent Infection with
MTB [pdf 1.6mb]
1b. Sandra M. Arend MD, PhD (Leiden University Medical Centre, The Netherlands):
Major Discrepancies Between M.tuberculosis - Specific
Interferon-γ Assays with Short Versus Prolonged
Incubation [pdf 642kb]
(Oral Presentation: Abstract 015)
1c. Morten Ruhwald (Copenhagen University Hospital, Denmark):
Introducing IP-10 as a Specific Diagnosis Marker for
Infection with M. tuberculosis [pdf 418kb]
(Oral Presentation: Abstract 028)
Session 2: Latency and the Risk of Active TB (Clinical Aspects): How Many Infected Persons Actually Develop Active Disease?
[n/a]. Peter Godfrey-Faussett BA, MBBS, DTM&H, FRCP (London School of Hygiene and Tropical Medicine, UK):
The Who, Why and When of Developing Tuberculosis
2a. Keertan Dheda MB.BCh. FCP(SA) PhD (Royal Free & University College Medical School, UK; University of Cape Town, South Africa):
IFN-γ Release Assays and Treatment of TB Infection: What Can We Learn from these Data? [pdf 236kb]
Session 3: A Re-examination of Pertinent Epidemiology Studies
3a. Ken Castro MD, PhD (CDC, Division of Tuberculosis Elimination, USA): Latency, Dormancy and Persistence:
What do Mice Studies Tell Us? [pdf 285kb]
3b. Dick Menzies MD, MSc. (McGill University, Canada)
Disagreement: What can we learn from it? [pdf 995kb]
Session 4: Public Health Implications of Studies with Assays that Use Highly Specific TB Antigens
4a. Andy Vernon MD (CDC, Division of Tuberculosis Eimination, USA):
Public Health Impact of Interferon Gamma Release Assays: A 2007 Perspective [pdf 1.4mb]
4b. Larry Geiter PhD (Aeras Global TB Vaccine Foundation, USA):
Public Health Implications of Studies with Assays that Use Highly Specific TB Antigens [pdf 114kb]
4c. M. A. Yassin (Liverpool School of Tropical Medicine, UK):
Could IFN-γ Assays Replace TST Surveys? Reflections from Information from Health Volunteers in a High TB Incidence Country [pdf 260kb]
(Oral Presentation: Abstract 039)
4d. Debbie-Ann Abrahams (South African TB Vaccine Initiative, University of Cape Town, South Africa):
Performance of QuantiFERON-TB Gold In-tube (QFT-GIT) Test for a Research Application in a Tuberculosis (TB) Endemic Area [pdf 1.5mb]
(Oral Presentation: Abstract 022)
4e. Hassan Mahomed (South African TB Vaccine Initiative, University of Cape Town, South Africa):
Preliminary Results on the Use of QuantiFERON-TB Gold (In-tube method) in a Large Cohort Study of TB in Adolescents in South Africa [pdf 110kb]
(Oral Presentation: Abstract 008)
4f. Antonino Catanzaro MD (University of California, San Diego, USA):
The Value of Sensitivity vs. Specificity [pdf 333kb]
Application of Interferon-γ Assays
Session 5: Health Care Worker Screening with IFN-γ Assays
5a. Madhukar Pai MD, PhD (McGill University, Canada):
Serial Testing with IFN-γ Assays: How Should We Define Conversions, Reversions and Thresholds? [pdf
1mb]
5b. Francis Drobniewski MB, BS, MA, PhD, DTM&H, FRCPath (Barts & The London, Queen Mary’s School of Medicine & Dentistry, UK):
Russian and British Healthcare Staff and IFN-γ Assays: What’s the Difference? [pdf 3.8mb]
5c. Toru Mori MD, PhD (National Institute of Infectious Diseases, Japan):
A Study of Healthcare Worker Screening with IFN-gamma Assays in Japan [pdf 300kb]
Session 6: Performance of the IFN-γ Assays in Contact and Outbreak Investigations
6a. Gerald Mazurek MD, PhD (CDC, Division of Tuberculosis Elimination, USA):
Tuberculin Skin Test versus QuantiFERON-TB Gold in U.S. Contact Investigations [pdf 151kb]
6b. Thomas Bodmer MD (Universität Bern, Switzerland):
Evaluating TB Contacts: Usefulness of a Whole-Blood IFN-γ Release Assay in a Military Setting [pdf 608kb]
[n/a]. Dr. Paul Vinton (Peninsula Health, Australia):
A Comparison of the Quantiferon-TB Gold-In Tube Assay and the Tuberculin Skin Test for Screening of Health Care Workers in Melbourne, Australia
(Oral Presentation: Abstract 062)
6c. Sandra M. Arend MD, PhD (Leiden University Medical Centre, The Netherlands):
A Supersized Contact Investigation with Comparison of Two IGRA [pdf 2.1mb]
6d. Madhukar Pai MD, PhD (McGill University, Canada):
Tuberculosis Infection Among Household Contacts in Rural India: Comparison of a Whole-Blood Interferon-gamma Assay with the Tuberculin Skin Test [pdf 955kb]
Session 7: Studies Using IFN-γ Assays in Various Settings
7a. Giovanni Ferrara MD, PhD (University of Modena & Reggio Emilia, Italy):
Using Interferon-γ Release Assays Day by Day in a Hospital Setting [pdf 451kb]
[n/a]. Monica Losi (University of Modena & Reggio Emilia, Italy):
Diagnosis of Latent Tuberculosis Infection in Patients with Hematological Malignancies: Use of the New IFN-γ Assays
(Oral Presentation: Abstract 051)
7b. Kevin L. Winthrop MD MPH (Oregon Health Sciences University, USA):
Blood vs. Skin Test: Comparison of Two Interferon-gamma Release Assays with the Tuberculin Skin Test in the
Diagnosis of MTB Infection Among Renal Dialysis Patients [pdf 221kb]
(Oral Presentation: Abstract 017)
7c. Christian Lienhardt MD, PhD (Institut de Recherche pour le Développement, IRD, France):
Risk Factors for Active Tuberculosis at Month 24 in Household Contacts of Smear Positive TB in Senegal [pdf 349kb]
(Oral Presentation: Abstract 036)
7d. Pernille Ravn MD, PhD (University Hvidovre Hospital, Denmark):
Diagnosis of M.tuberculosis Infection in Vulnerable Groups: Children in High Endemic Regions [pdf 759kb]
7e. Naasha J. Talati (Emory University, USA):
Comparison of Tuberculin Skin Test and Interferon-γ Release Assays for Diagnosis of Latent TB Infection Among HIV Positive Persons [pdf 227kb]
(Oral Presentation: Abstract 061)
7f. Cristina Russo (Bambino Gesú Paediatric Hospital, Italy):
Agreement Between Classic Diagnostic Procedures and the New INF-γ Release Assay for Detection of TB Disease in Children [pdf 551kb]
7g. Gediminas Matulis MD (Universität Bern, Switzerland):
Performance of an IFN-gamma Assay for the Diagnosis of LTBI in Immunosuppressed Rheumatologic Out-Patients: A Prospective Study [pdf 181kb]
Session 8: Cost-Effectiveness and Health Care Effectiveness of IFN-γ Assays
8a. PD Dr. Roland Diel (University of Düsseldorf, Germany):
Cost-Effectiveness of IGRA Screening for the Treatment of Latent Tuberculosis in Germany [pdf 508kb]
8b. Dick Menzies MD, MPH (McGill University, Canada):
A Comparison of the Cost-Effectiveness of Interferon-gamma Release Assays with Tuberculin Skin Testing for
Screening Contacts or New Immigrants to Canada [pdf 163kb]
8c. Masae Kawamura MD (San Francisco Dept. of Public Health, USA):
The Cost Effectiveness of IGRA Diagnostics: Theoretical and Practical Perspectives [pdf 215kb]
8d. Jennifer Grinsdale (San Francisco Dept. of Public Health, USA):
Community Based Tuberculosis Screening Using QuantiFERON-TB Gold: The San Francisco Experience [pdf 52kb]
(Oral Presentation: Abstract 041)
Plenary Sessions and Oral Abstract Presentations [pdf 98kb]
Download
all abstracts [pdf 340kb]
Posters
|
